What is the latest ALKEM stock price?
The latest stored price for ALKEM is Rs 5,279.00 as of 2026-10-09.
gimli
ALKEM stock AI analysis
ALKEM Stock AI Analysis: Price, PE, 50DMA, Shareholding and Peers
ALKEM LABORATORIES LTD. is a mid-cap stock in Healthcare. This Gimli page shows the latest available ALKEM price, returns, 50DMA/200DMA trend, PE, ROE, ROCE, financials, shareholding pattern, and industry peers for Indian stock screening research.
Price
₹5,279.00
1W return
+1.13%
1M return
+2.72%
3M return
-6.54%
6M return
-1.70%
1Y return
-3.68%
Market cap
₹63,118.36 cr
PE
27.42
PB
4.40
ROE
+17.19%
ROCE
+20.07%
RSI
49.57
Turnover
₹50.72 cr
Why it can matter in screens
- Momentum: ALKEM is below 50DMA, below 200DMA; RSI is 49.57.
- Returns: 1D +0.56%, 1W +1.13%, 1M +2.72%, 3M -6.54%, 1Y -3.68%.
- Trend levels: 52W high ₹5,882.50, 52W low ₹5,051.00, off high -10.26%.
- Liquidity: latest turnover is ₹50.72 cr; volume vs 20D is +0.56%.
- Valuation/profitability: PE 27.42, PB 4.40, ROE +17.19%, ROCE +20.07%.
- Growth: 3Y sales CAGR +8.74%, 3Y profit CAGR +32.73%.
Quick Answers
Is ALKEM above its 50DMA and 200DMA?
ALKEM is below 50DMA, below 200DMA. The latest 50DMA is 5,359.90 and the latest 200DMA is 5,477.68.
What are ALKEM PE, ROE and ROCE?
ALKEM has PE 27.42, ROE +17.19%, and ROCE +20.07% in Gimli's latest available snapshot.
How has ALKEM performed recently?
ALKEM has returned +2.72% over 1 month, -6.54% over 3 months, and -3.68% over 12 months in the latest stored data.
Is this stock page investment advice?
No. This page is a data snapshot for screening and research. It is not buy, sell, legal, tax, or investment advice.
Financials and Ownership
Quarterly income statement
| Period | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 3,603.32 cr | 582.49 cr | 236.46 cr | 19.77 |
| 2025-12-31 | 3,736.82 cr | 918.31 cr | 636.02 cr | 53.19 |
| 2025-09-30 | 4,000.99 cr | 1,024.46 cr | 765.06 cr | 63.99 |
| 2025-06-30 | 3,371.14 cr | 888.47 cr | 664.26 cr | 55.56 |
| 2025-03-31 | 3,143.75 cr | 537.25 cr | 305.86 cr | 25.57 |
| 2024-12-31 | 3,374.28 cr | 852.38 cr | 625.82 cr | 52.34 |
| 2024-09-30 | 3,414.67 cr | 887.31 cr | n/a | 57.60 |
| 2024-06-30 | 3,031.82 cr | 728.95 cr | 545.16 cr | 45.60 |
Annual income statement
| Year | Revenue | EBITDA | PAT | EPS |
|---|---|---|---|---|
| 2026-03-31 | 14,712.27 cr | 3,413.73 cr | 2,301.80 cr | 192.51 |
| 2025-03-31 | 12,964.52 cr | 3,005.89 cr | 2,165.48 cr | 181.11 |
| 2024-03-31 | 12,439.24 cr | 2,418.14 cr | 1,795.77 cr | 150.19 |
| 2023-03-31 | 11,440.35 cr | 1,708.94 cr | 984.17 cr | 82.31 |
| 2022-03-31 | 9,029.70 cr | 2,189.08 cr | 1,541.25 cr | nan |
Balance sheet
| Period | Assets | Cash | Debt | Equity |
|---|---|---|---|---|
| 2026-03-31 | 20,872.97 cr | 247.91 cr | 2,047.16 cr | 14,348.93 cr |
| 2025-03-31 | 17,691.10 cr | 304.14 cr | 1,380.90 cr | 12,433.63 cr |
| 2024-03-31 | 15,574.90 cr | 455.07 cr | 1,418.41 cr | 10,714.40 cr |
| 2023-03-31 | 13,756.65 cr | 273.80 cr | 1,396.68 cr | 9,435.00 cr |
| 2022-03-31 | 14,069.19 cr | 232.18 cr | 2,668.19 cr | 8,847.33 cr |
Cash flow
| Period | OCF | FCF | Cash change |
|---|---|---|---|
| 2026-03-31 | 1,963.03 cr | 1,345.77 cr | n/a |
| 2025-03-31 | 1,912.84 cr | 1,237.22 cr | n/a |
| 2024-03-31 | 1,948.07 cr | 1,688.78 cr | n/a |
| 2023-03-31 | 1,682.50 cr | 1,449.59 cr | n/a |
| 2022-03-31 | 1,111.02 cr | 772.14 cr | n/a |
Shareholding Trend
| Period | Promoter | FII/FPI | DII | MF | Retail | Pledge |
|---|---|---|---|---|---|---|
| 2026-06-30 | +49.70% | +10.42% | +22.63% | +16.71% | +17.25% | +0.00% |
| 2026-03-31 | +51.20% | +10.16% | +21.40% | +15.57% | +17.25% | +0.00% |
| 2025-12-31 | +51.20% | +9.97% | +21.54% | +16.06% | +17.30% | +0.00% |
| 2025-09-30 | +51.20% | +9.48% | +21.93% | +16.94% | +17.40% | +0.00% |
| 2025-06-30 | +53.04% | +9.11% | +21.80% | +16.67% | +16.05% | +0.00% |
| 2025-03-31 | +55.13% | +9.41% | +19.42% | +14.97% | +16.05% | +0.00% |
| 2024-12-31 | +55.66% | +10.15% | +18.01% | +14.01% | +16.18% | +0.00% |
| 2024-09-30 | +55.66% | +9.02% | +19.21% | +14.94% | +16.10% | +0.00% |
| 2024-06-30 | +56.38% | +8.69% | +18.57% | +14.72% | +16.36% | +0.00% |
| 2024-03-31 | +56.74% | +9.11% | +15.63% | +11.92% | +18.52% | +0.00% |
| 2023-12-31 | +56.74% | +8.49% | +15.91% | +12.08% | +18.86% | +0.00% |
| 2023-09-30 | +56.74% | +6.03% | +17.64% | +13.05% | +19.59% | +0.00% |
| 2023-06-30 | +57.16% | +5.64% | +16.34% | +11.45% | +20.86% | +0.00% |
| 2023-03-31 | +57.16% | +4.44% | +16.69% | +10.19% | +21.70% | +0.00% |
| 2022-12-31 | +57.16% | +4.41% | +16.44% | +10.06% | +21.99% | +0.00% |
| 2022-09-30 | +57.16% | +4.46% | +15.74% | +9.42% | +22.65% | +0.00% |
| 2022-06-30 | +57.14% | +0.00% | +19.77% | n/a | n/a | n/a |
| 2022-03-31 | +57.13% | +0.00% | +19.55% | n/a | n/a | +0.00% |
| 2021-12-31 | +57.13% | +0.00% | +19.34% | n/a | n/a | +0.00% |
| 2021-09-30 | +58.84% | +0.00% | +19.32% | n/a | n/a | +0.00% |
Industry Peers
| Symbol | Name | Mcap | PE | ROE | 1Y |
|---|---|---|---|---|---|
| SUNPHARMA | SUN PHARMACEUTICAL IND L | 422,282.96 cr | 34.857273 | +15.50% | +6.12% |
| DIVISLAB | DIVI S LABORATORIES LTD | 247,947.67 cr | 85.088426 | +18.37% | +52.32% |
| TORNTPHARM | TORRENT PHARMACEUTICALS L | 157,610.64 cr | 72.265309 | +17.33% | +31.16% |
| APOLLOHOSP | APOLLO HOSPITALS ENTER. L | 115,423.17 cr | 58.937484 | +21.03% | +4.32% |
| ZYDUSLIFE | ZYDUS LIFESCIENCES LTD | 112,446.65 cr | 25.058308 | +16.04% | +12.37% |
| LAURUSLABS | LAURUS LABS LIMITED | 109,947.20 cr | 100.670416 | +21.77% | +135.42% |
| CIPLA | CIPLA LTD | 105,094.85 cr | 31.162389 | +10.25% | -14.02% |
| DRREDDY | DR. REDDY S LABORATORIES | 99,661.60 cr | 30.096514 | +9.23% | -3.94% |
Try these prompts
- Analyze ALKEM LABORATORIES. with valuation, momentum and industry peers
- Compare ALKEM with other Healthcare stocks
- Show mid-cap stocks in Healthcare above 50DMA with positive 1M return
- Find Healthcare stocks with improving momentum and reasonable valuation
Related screen ideas
- View Healthcare stocks
- View mid-cap stocks
- Find stocks above 50DMA
- Compare ALKEM with other Healthcare stocks
Data snapshot: 2026-10-09. Not investment advice.